Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].

Demidov L, Samoylenko I, Kharkevich G, Orlova K, Moiseenko V, Utyashev I, Stroyakovskiy D, Kozlov V, Zimina A, Mochalova A, Demidova S, Lyadova M, Kutkovich A, Skopin P, Kovalenko N, Safina S, Volkov V, Semiletova Y, Vaschenko V, Kislov N, Poltoratskiy A, Shumskaya I, Kolomiets S, Sobolev A, Belogortsev I, Odintsova S, Rastogi S, Andabekov T, Penkov K, Semenova A, Obukhov A, Belyakovsky V, Yurchenkov A, Gladkov O, Neve R, Falaleeva N, Poddubskaya E, Vaibhav A, Kirtbaya D, Chapko Y, Smagina M, Fadeeva N, Sorokina I, Mikhailova E, Linkova Y, Zinkina-Orikhan A, Lutskii A, Gabidullin R, Rzaev R, Kryukov F

Open source

DOI: 10.1016/j.ejca.2025.115732
Published: 2025 Oct 1
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.115732,
  title = {Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].},
  author = {Demidov L and Samoylenko I and Kharkevich G and Orlova K and Moiseenko V and Utyashev I and Stroyakovskiy D and Kozlov V and Zimina A and Mochalova A and Demidova S and Lyadova M and Kutkovich A and Skopin P and Kovalenko N and Safina S and Volkov V and Semiletova Y and Vaschenko V and Kislov N and Poltoratskiy A and Shumskaya I and Kolomiets S and Sobolev A and Belogortsev I and Odintsova S and Rastogi S and Andabekov T and Penkov K and Semenova A and Obukhov A and Belyakovsky V and Yurchenkov A and Gladkov O and Neve R and Falaleeva N and Poddubskaya E and Vaibhav A and Kirtbaya D and Chapko Y and Smagina M and Fadeeva N and Sorokina I and Mikhailova E and Linkova Y and Zinkina-Orikhan A and Lutskii A and Gabidullin R and Rzaev R and Kryukov F},
  year = {2025},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2025.115732},
  url = {https://doi.org/10.1016/j.ejca.2025.115732}
}

RIS

TY  - JOUR
TI  - Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].
AU  - Demidov L
AU  - Samoylenko I
AU  - Kharkevich G
AU  - Orlova K
AU  - Moiseenko V
AU  - Utyashev I
AU  - Stroyakovskiy D
AU  - Kozlov V
AU  - Zimina A
AU  - Mochalova A
AU  - Demidova S
AU  - Lyadova M
AU  - Kutkovich A
AU  - Skopin P
AU  - Kovalenko N
AU  - Safina S
AU  - Volkov V
AU  - Semiletova Y
AU  - Vaschenko V
AU  - Kislov N
AU  - Poltoratskiy A
AU  - Shumskaya I
AU  - Kolomiets S
AU  - Sobolev A
AU  - Belogortsev I
AU  - Odintsova S
AU  - Rastogi S
AU  - Andabekov T
AU  - Penkov K
AU  - Semenova A
AU  - Obukhov A
AU  - Belyakovsky V
AU  - Yurchenkov A
AU  - Gladkov O
AU  - Neve R
AU  - Falaleeva N
AU  - Poddubskaya E
AU  - Vaibhav A
AU  - Kirtbaya D
AU  - Chapko Y
AU  - Smagina M
AU  - Fadeeva N
AU  - Sorokina I
AU  - Mikhailova E
AU  - Linkova Y
AU  - Zinkina-Orikhan A
AU  - Lutskii A
AU  - Gabidullin R
AU  - Rzaev R
AU  - Kryukov F
PY  - 2025
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2025.115732
UR  - https://doi.org/10.1016/j.ejca.2025.115732
ER  -

APA

L, D., I, S., G, K., K, O., V, M., I, U., D, S., V, K., A, Z., A, M., S, D., M, L., A, K., P, S., N, K., S, S., V, V., Y, S., V, V., N, K., A, P., I, S., S, K., A, S., I, B., S, O., S, R., T, A., K, P., A, S., A, O., V, B., A, Y., O, G., R, N., N, F., E, P., A, V., D, K., Y, C., M, S., N, F., I, S., E, M., Y, L., A, Z., A, L., R, G., R, R., & F, K. (2025). Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2025.115732

Source records

pubmed · retrieved 2026-09-26T20:44:01.805Z